Interventions to reduce neurological symptoms in patients with GBM receiving radiotherapy: From theory to clinical practice

Lucia Palombi, Paolo Marchetti, Maurizio Salvati, Mattia Falchetto Osti, Luigi Frati, Alessandro Frati

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Patients affected by glioblastoma often develop cerebral oedema as a life-threatening complication. Although there is no approved pharmacological intervention, such cerebral oedema is usually treated with dexamethasone. Dexamethasone has been shown in experimental studies to reduce cerebral oedema with only few mineralocorticoid side-effects. The goal of our study was to examine its efficacy in reducing the emergence of neurological deficits during the Stupp protocol. Patients and Methods: We studied a retrospective cohort of 459 patients, assigned in controlled groups: in group A, patients received radiochemotherapy followed by adjuvant chemotherapy; in group B, patients received an equivalent combined treatment with dexamethasone. Results: The frequency of neurological symptoms was significantly lower in dexamethasone-treated patients. Conclusion: Early diagnosis and prevention of cerebral oedema are important because functional consequences can be anticipated with an appropriate medical treatment. Thus, our study reveals that dexamethasone acts to prevent the appearance of neurological symptoms in patients with brain tumour.

Original languageEnglish
Pages (from-to)2423-2427
Number of pages5
JournalAnticancer Research
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Radiotherapy
Dexamethasone
Brain Edema
Mineralocorticoids
Chemoradiotherapy
Adjuvant Chemotherapy
Glioblastoma
Brain Neoplasms
Early Diagnosis
Pharmacology
Therapeutics

Keywords

  • Brain tumour
  • Dexamethasone
  • GBM
  • Neurological symptoms
  • Oedema
  • QoL

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Interventions to reduce neurological symptoms in patients with GBM receiving radiotherapy : From theory to clinical practice. / Palombi, Lucia; Marchetti, Paolo; Salvati, Maurizio; Osti, Mattia Falchetto; Frati, Luigi; Frati, Alessandro.

In: Anticancer Research, Vol. 38, No. 4, 01.04.2018, p. 2423-2427.

Research output: Contribution to journalArticle

Palombi, Lucia ; Marchetti, Paolo ; Salvati, Maurizio ; Osti, Mattia Falchetto ; Frati, Luigi ; Frati, Alessandro. / Interventions to reduce neurological symptoms in patients with GBM receiving radiotherapy : From theory to clinical practice. In: Anticancer Research. 2018 ; Vol. 38, No. 4. pp. 2423-2427.
@article{b6df02d71d014f199f073fe61dab6337,
title = "Interventions to reduce neurological symptoms in patients with GBM receiving radiotherapy: From theory to clinical practice",
abstract = "Background: Patients affected by glioblastoma often develop cerebral oedema as a life-threatening complication. Although there is no approved pharmacological intervention, such cerebral oedema is usually treated with dexamethasone. Dexamethasone has been shown in experimental studies to reduce cerebral oedema with only few mineralocorticoid side-effects. The goal of our study was to examine its efficacy in reducing the emergence of neurological deficits during the Stupp protocol. Patients and Methods: We studied a retrospective cohort of 459 patients, assigned in controlled groups: in group A, patients received radiochemotherapy followed by adjuvant chemotherapy; in group B, patients received an equivalent combined treatment with dexamethasone. Results: The frequency of neurological symptoms was significantly lower in dexamethasone-treated patients. Conclusion: Early diagnosis and prevention of cerebral oedema are important because functional consequences can be anticipated with an appropriate medical treatment. Thus, our study reveals that dexamethasone acts to prevent the appearance of neurological symptoms in patients with brain tumour.",
keywords = "Brain tumour, Dexamethasone, GBM, Neurological symptoms, Oedema, QoL",
author = "Lucia Palombi and Paolo Marchetti and Maurizio Salvati and Osti, {Mattia Falchetto} and Luigi Frati and Alessandro Frati",
year = "2018",
month = "4",
day = "1",
doi = "10.21873/anticanres.12494",
language = "English",
volume = "38",
pages = "2423--2427",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Interventions to reduce neurological symptoms in patients with GBM receiving radiotherapy

T2 - From theory to clinical practice

AU - Palombi, Lucia

AU - Marchetti, Paolo

AU - Salvati, Maurizio

AU - Osti, Mattia Falchetto

AU - Frati, Luigi

AU - Frati, Alessandro

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Patients affected by glioblastoma often develop cerebral oedema as a life-threatening complication. Although there is no approved pharmacological intervention, such cerebral oedema is usually treated with dexamethasone. Dexamethasone has been shown in experimental studies to reduce cerebral oedema with only few mineralocorticoid side-effects. The goal of our study was to examine its efficacy in reducing the emergence of neurological deficits during the Stupp protocol. Patients and Methods: We studied a retrospective cohort of 459 patients, assigned in controlled groups: in group A, patients received radiochemotherapy followed by adjuvant chemotherapy; in group B, patients received an equivalent combined treatment with dexamethasone. Results: The frequency of neurological symptoms was significantly lower in dexamethasone-treated patients. Conclusion: Early diagnosis and prevention of cerebral oedema are important because functional consequences can be anticipated with an appropriate medical treatment. Thus, our study reveals that dexamethasone acts to prevent the appearance of neurological symptoms in patients with brain tumour.

AB - Background: Patients affected by glioblastoma often develop cerebral oedema as a life-threatening complication. Although there is no approved pharmacological intervention, such cerebral oedema is usually treated with dexamethasone. Dexamethasone has been shown in experimental studies to reduce cerebral oedema with only few mineralocorticoid side-effects. The goal of our study was to examine its efficacy in reducing the emergence of neurological deficits during the Stupp protocol. Patients and Methods: We studied a retrospective cohort of 459 patients, assigned in controlled groups: in group A, patients received radiochemotherapy followed by adjuvant chemotherapy; in group B, patients received an equivalent combined treatment with dexamethasone. Results: The frequency of neurological symptoms was significantly lower in dexamethasone-treated patients. Conclusion: Early diagnosis and prevention of cerebral oedema are important because functional consequences can be anticipated with an appropriate medical treatment. Thus, our study reveals that dexamethasone acts to prevent the appearance of neurological symptoms in patients with brain tumour.

KW - Brain tumour

KW - Dexamethasone

KW - GBM

KW - Neurological symptoms

KW - Oedema

KW - QoL

UR - http://www.scopus.com/inward/record.url?scp=85045117887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045117887&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12494

DO - 10.21873/anticanres.12494

M3 - Article

C2 - 29599372

AN - SCOPUS:85045117887

VL - 38

SP - 2423

EP - 2427

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -